937 results on '"Soria, J.-C."'
Search Results
2. Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
3. Small cell lung cancer: a slightly less orphan disease after immunotherapy
4. Intervention strategies for microbial therapeutics in cancer immunotherapy
5. Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors
6. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
7. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
8. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
9. Epigenetic modifiers as new immunomodulatory therapies in solid tumours
10. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
11. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
12. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
13. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
14. Consensus on precision medicine for metastatic cancers: a report from the MAP conference
15. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
16. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
17. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
18. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
19. Prioritizing targets for precision cancer medicine
20. 34P Gustave Roussy Match-R study: A descriptive analysis of the molecular target population
21. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
22. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
23. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
24. Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database
25. Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer
26. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
27. 1661MO Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma
28. 639P Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
29. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
30. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
31. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma
32. Annals of Oncology: un bon travail
33. 3D waterfall plots: a better graphical representation of tumor response in oncology
34. Reply to the letter to the editor ‘Is the pursuit of a higher impact factor fully justified?’
35. Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency
36. P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
37. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses
38. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
39. Supplement to: Rociletinib in EGFR-mutated non-small-cell lung cancer.
40. Added value of molecular targeted agents in oncology
41. Évaluation d’un programme de formation à la communication dans le cadre d’essais thérapeutiques de phase I selon l’expérience des oncologues
42. Congrès Targeted Anticancer Therapies — TAT 2014
43. Apport de l’imagerie dans l’évaluation des masses et métastases cardiaques
44. Low skeletal muscle is associated with toxicity in patients included in phase I trials
45. Environmental emissions, public health and lung cancer risk
46. Annals of oncology in 2015: the year in review
47. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
48. La vie d’une molécule, des essais à l’enregistrement : spécificité de l’oncologie
49. 19P Therapeutic targets in non-small cell lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and its associated molecular landscape
50. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.